MAXITROL

This brand name is authorized in Brazil, Canada, Ecuador, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Israel, Lithuania, Mexico, Nigeria, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom, United States

Active ingredients

The drug MAXITROL contains a combination of these active pharmaceutical ingredients (APIs):

1 Neomycin UNII 057Y626693 - NEOMYCIN SULFATE

Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code. Read about Neomycin

2 Polymyxin B UNII 19371312D4 - POLYMYXIN B SULFATE

Polymixin B is bactericidal against a wide range of gram negative bacilli. It exerts a bactericidal effect by binding to acid phospholipids in the cell wall and membranes of the bacterium, thereby rendering ineffective the osmotic barrier normally provided by the cell membrane. Read about Polymyxin B

3 Dexamethasone UNII 7S5I7G3JQL - DEXAMETHASONE

Dexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. It has an approximately 7 times greater anti-inflammatory potency than prednisolone, another commonly prescribed corticosteroid. At high doses it reduces the immune response. Read about Dexamethasone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MAXITROL Eye drops, suspension	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01CA01	Dexamethasone and antiinfectives	S Sensory organs → S01 Ophthalmologicals → S01C Antiinflammatory agents and antiinfectives in combination → S01CA Corticosteroids and antiinfectives in combination
Discover more medicines within S01CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 500902601166312, 500902602170313
Country: CA	Health Products and Food Branch	Identifier(s): 00042676, 00358177
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 1072-MEE-0615, 25.910-09-04
Country: EE	Ravimiamet	Identifier(s): 1124301
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 42610, 5730-2005-01, PL00649-5915R
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 486886
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 14965, 43787
Country: HK	Department of Health Drug Office	Identifier(s): 16912, 17041
Country: IE	Health Products Regulatory Authority	Identifier(s): 73105
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 3246, 742
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1012840, 1012841, 1066138, 1077966, 1078906, 1078907, 1085353, 1085793, 1087839
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 63496, 64134
Country: NG	Registered Drug Product Database	Identifier(s): 04-1570
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 945, 946
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100042165, 100046170, 100079441, 100132336, 100257701, 100257753, 100257990, 100260809, 100265882, 100283443, 100288593, 100324840, 100343205, 100360853, 100360988, 100365508, 100383334, 100393657, 100398991, 100406029, 100406874, 100421537, 100426300, 100455218, 100458049, 100458277, 100458596, 100460302, 100460310, 100467943
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W63598001
Country: SG	Health Sciences Authority	Identifier(s): 04358P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 10283441
Country: US	FDA, National Drug Code	Identifier(s): 0065-0631, 0078-0771, 0998-0630